Ironwood Pharmaceuticals, Inc. is a biotechnology company. The Company is advancing product opportunities in areas of unmet need, including irritable bowel syndrome with constipation (IBS C), and chronic idiopathic constipation (CIC), hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease (uncontrolled GERD), and vascular and fibrotic diseases. It operates in human therapeutics business segment. Its product, linaclotide, is available to adult men and women suffering from IBS C or CIC in the United States under the trademarked name LINZESS, and is available to adult men and women suffering from IBS C in certain European countries under the trademarked name CONSTELLA. It is also advancing IW-3718, a gastric retentive formulation of a bile acid sequestrant with the potential to provide symptomatic relief in patients with uncontrolled GERD. Its vascular/fibrotic programs include IW-1973 and IW-1701, which targets soluble guanylate cyclase (sGC).
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology & Medical Research
- Sub-Industry: Biotechnology
- Symbol: NASDAQ:IRWD
- CUSIP: 46333X10
- Web: www.ironwoodpharma.com
Capitalization:- Market Cap: $2.32165 billion
- Outstanding Shares: 149,591,000
Average Prices:- 50 Day Moving Avg: $15.49
- 200 Day Moving Avg: $17.03
- 52 Week Range: $12.48 - $19.94
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -30.46
- P/E Growth: -0.26
Sales & Book Value:- Annual Revenue: $270.81 million
- Price / Sales: 8.75
- Book Value: $0.03 per share
- Price / Book: 528.00
Profitability:- EBIDTA: ($84,770,000.00)
- Net Margins: -52.97%
- Return on Equity: -333.83%
- Return on Assets: -18.83%
Debt:- Debt-to-Equity Ratio: 79.64%
- Current Ratio: 4.27%
- Quick Ratio: 4.27%
Misc:- Average Volume: 1.22 million shs.
- Beta: 1.48
- Short Ratio: 11.15
Frequently Asked Questions for Ironwood Pharmaceuticals (NASDAQ:IRWD)
What is Ironwood Pharmaceuticals' stock symbol?
Ironwood Pharmaceuticals trades on the NASDAQ under the ticker symbol "IRWD."
How were Ironwood Pharmaceuticals' earnings last quarter?
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) issued its quarterly earnings data on Thursday, August, 3rd. The company reported ($0.28) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.23) by $0.05. The firm earned $65.10 million during the quarter, compared to analyst estimates of $70 million. Ironwood Pharmaceuticals had a negative net margin of 52.97% and a negative return on equity of 333.83%. The firm's revenue was up 19.7% compared to the same quarter last year. During the same period last year, the business earned ($0.16) EPS. View Ironwood Pharmaceuticals' Earnings History.
When will Ironwood Pharmaceuticals make its next earnings announcement?
Where is Ironwood Pharmaceuticals' stock going? Where will Ironwood Pharmaceuticals' stock price be in 2017?
9 brokers have issued 1-year price targets for Ironwood Pharmaceuticals' stock. Their predictions range from $13.00 to $21.00. On average, they anticipate Ironwood Pharmaceuticals' stock price to reach $18.13 in the next year. View Analyst Ratings for Ironwood Pharmaceuticals.
Are investors shorting Ironwood Pharmaceuticals?
Ironwood Pharmaceuticals saw a increase in short interest during the month of August. As of August 15th, there was short interest totalling 16,348,161 shares, an increase of 16.0% from the July 31st total of 14,098,775 shares. Based on an average daily trading volume, of 1,492,918 shares, the short-interest ratio is currently 11.0 days. Currently, 12.3% of the company's stock are short sold.
Who are some of Ironwood Pharmaceuticals' key competitors?
Some companies that are related to Ironwood Pharmaceuticals include ACADIA Pharmaceuticals (ACAD), Bio-Techne Corp (TECH), PAREXEL International Corporation (PRXL), FibroGen (FGEN), Puma Biotechnology (PBYI), Nektar Therapeutics (NKTR), WuXi PharmaTech (Cayman) (WX), Portola Pharmaceuticals (PTLA), Ligand Pharmaceuticals Incorporated (LGND), Blueprint Medicines Corporation (BPMC), Sage Therapeutics (SAGE), Intrexon Corporation (XON), Immunomedics (IMMU), Foundation Medicine (FMI), Biohaven Pharmaceutical Holding Co Ltd (BHVN), Esperion Therapeutics (ESPR), Momenta Pharmaceuticals (MNTA) and Genus plc (GNS).
Who are Ironwood Pharmaceuticals' key executives?
Ironwood Pharmaceuticals' management team includes the folowing people:
- Peter M. Hecht Ph.D., Chief Executive Officer, Director
- Thomas Graney, Chief Financial Officer, Senior Vice President - Finance, Corporate Strategy
- Mark G. Currie Ph.D., Senior Vice President, Chief Scientific Officer, President - Research and Development
- Thomas A. McCourt, Senior Vice President - Marketing and Sales, Chief Commercial Officer
- Halley E. Gilbert Esq., Senior Vice President, Chief Legal Officer, Secretary
- Christopher I. Wright M.D. Ph.D., Senior Vice President - Global Development and Chief Development Officer
- Terrance G. McGuire, Non-Executive Independent Chairman of the Board
- Andrew Dreyfus, Independent Director
- Marsha H. Fanucci, Independent Director
- Julie H. McHugh, Independent Director
Who owns Ironwood Pharmaceuticals stock?
Ironwood Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include FMR LLC (12.59%), Vanguard Group Inc. (7.24%), Janus Henderson Group PLC (5.90%), State Street Corp (3.35%), EcoR1 Capital LLC (2.78%) and Pictet Asset Management Ltd. (1.28%). Company insiders that own Ironwood Pharmaceuticals stock include Edward P Owens, Gina Consylman, Halley E Gilbert, Julie Mchugh, Lawrence S Olanoff, Mark G Currie, Peter M Hecht, Thomas A Mccourt and Thomas Graney. View Institutional Ownership Trends for Ironwood Pharmaceuticals.
Who sold Ironwood Pharmaceuticals stock? Who is selling Ironwood Pharmaceuticals stock?
Ironwood Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Spark Investment Management LLC, Goldman Sachs Group Inc., Blue Jay Capital Management LLC, Gotham Asset Management LLC, Artal Group S.A., Alliancebernstein L.P. and Bank of Montreal Can. Company insiders that have sold Ironwood Pharmaceuticals stock in the last year include Gina Consylman, Halley E Gilbert, Julie Mchugh, Lawrence S Olanoff, Peter M Hecht and Thomas A Mccourt. View Insider Buying and Selling for Ironwood Pharmaceuticals.
Who bought Ironwood Pharmaceuticals stock? Who is buying Ironwood Pharmaceuticals stock?
Ironwood Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, EcoR1 Capital LLC, Penn Capital Management Co. Inc., State Street Corp, State of Wisconsin Investment Board, New York State Common Retirement Fund, Pictet Asset Management Ltd. and Vanguard Group Inc.. View Insider Buying and Selling for Ironwood Pharmaceuticals.
How do I buy Ironwood Pharmaceuticals stock?
Shares of Ironwood Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Ironwood Pharmaceuticals' stock price today?
One share of Ironwood Pharmaceuticals stock can currently be purchased for approximately $15.84.
MarketBeat Community Rating for Ironwood Pharmaceuticals (NASDAQ IRWD)MarketBeat's community ratings are surveys of what our community members think about Ironwood Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Ironwood Pharmaceuticals (NASDAQ:IRWD) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 5 Hold Ratings, 4 Buy Ratings |
| Consensus Rating: | Hold (Score: 2.44) |
| Consensus Price Target: | $18.13 (14.43% upside) |
Analysts' Ratings History for Ironwood Pharmaceuticals (NASDAQ:IRWD)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 8/25/2017 | Mizuho | Reiterated Rating | Buy | $23.00 -> $20.00 | Medium |  |
| 8/21/2017 | Cowen and Company | Set Price Target | Buy | $20.00 | Medium | |
| 7/22/2017 | Wells Fargo & Company | Set Price Target | Buy | $19.00 | Low | |
| 7/21/2017 | Wood & Company | Downgrade | Overweight -> Neutral | | Low | |
| 7/21/2017 | J P Morgan Chase & Co | Reiterated Rating | Overweight -> Neutral | $20.00 -> $19.00 | High | |
| 6/16/2017 | Wedbush | Reiterated Rating | Neutral | $13.00 | Low | |
| 3/13/2017 | BTIG Research | Reiterated Rating | Buy | $18.00 -> $21.00 | Low | |
| 2/22/2017 | Barclays PLC | Reiterated Rating | Equal Weight -> Equal Weight | $13.00 -> $16.00 | N/A | |
| 9/27/2016 | WallachBeth Capital | Boost Price Target | Hold | $15.00 -> $17.00 | N/A | |
| 8/8/2016 | Leerink Swann | Reiterated Rating | Market Perform | $10.00 -> $14.00 | N/A | |
| 4/28/2016 | JP Morgan Cazenove | Reiterated Rating | Overweight | $15.00 | N/A | |
| 4/26/2016 | Morgan Stanley | Reiterated Rating | Hold | | N/A | |
| 3/21/2016 | Goldman Sachs Group, Inc. (The) | Initiated Coverage | Neutral | $14.00 | N/A | |
(Data available from 9/23/2015 forward)
Earnings History for Ironwood Pharmaceuticals (NASDAQ:IRWD)Earnings History by Quarter for Ironwood Pharmaceuticals (NASDAQ IRWD)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/1/2017 | | | | | | | N/A | |
| 8/3/2017 | Q2 2017 | ($0.23) | ($0.28) | $70.00 million | $65.10 million | View | Listen | |
| 5/8/2017 | Q1 2017 | ($0.19) | ($0.33) | $69.39 million | $52.16 million | View | Listen | |
| 2/21/2017 | Q416 | ($0.24) | ($0.12) | $77.34 million | $87.50 million | View | Listen | |
| 11/3/2016 | Q316 | ($0.23) | ($0.18) | $60.01 million | $66.00 million | View | N/A | |
| 8/4/2016 | Q216 | ($0.15) | ($0.16) | $54.49 million | $54.40 million | View | N/A | |
| 5/9/2016 | Q116 | ($0.14) | ($0.08) | $52.97 million | $66.00 million | View | N/A | |
| 2/18/2016 | Q415 | ($0.17) | ($0.10) | $44.78 million | $53.30 million | View | Listen | |
| 11/3/2015 | Q315 | ($0.20) | ($0.25) | $39.81 million | $39.60 million | View | Listen | |
| 8/5/2015 | Q215 | ($0.22) | ($0.34) | $36.08 million | $27.74 million | View | N/A | |
| 5/5/2015 | Q115 | ($0.23) | ($0.24) | $32.30 million | $28.90 million | View | N/A | |
| 2/12/2015 | Q414 | ($0.21) | ($0.27) | $35.20 million | $38.10 million | View | Listen | |
| 11/4/2014 | Q314 | ($0.32) | ($0.30) | $21.20 million | $16.90 million | View | Listen | |
| 8/4/2014 | Q214 | ($0.36) | ($0.38) | $15.75 million | $6.84 million | View | Listen | |
| 4/29/2014 | Q1 | ($0.45) | ($0.38) | $8.52 million | $14.60 million | View | Listen | |
| 1/21/2014 | Q413 | ($0.50) | ($0.43) | $7.13 million | $5.00 million | View | Listen | |
| 10/22/2013 | Q313 | ($0.57) | ($0.51) | $6.54 million | $4.90 million | View | N/A | |
| 7/23/2013 | Q2 2013 | ($0.70) | ($0.57) | $6.32 million | $9.70 million | View | N/A | |
| 4/23/2013 | Q1 2013 | ($0.71) | ($0.87) | $8.94 million | $3.30 million | View | N/A | |
| 1/15/2013 | Q4 2012 | ($0.49) | ($0.41) | $16.17 million | $27.00 million | View | N/A | |
| 10/16/2012 | | $0.17 | $0.42 | | | View | N/A | |
| 7/17/2012 | | ($0.31) | ($0.38) | | | View | N/A | |
| 5/1/2012 | | ($0.23) | ($0.34) | | | View | N/A | |
| 2/28/2012 | | ($0.11) | ($0.07) | | | View | N/A | |
| 11/7/2011 | | ($0.20) | ($0.21) | | | View | N/A | |
| 8/11/2011 | | ($0.18) | ($0.19) | | | View | N/A | |
| 5/12/2011 | | ($0.17) | ($0.19) | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Ironwood Pharmaceuticals (NASDAQ:IRWD)2017 EPS Consensus Estimate: ($0.75)
2018 EPS Consensus Estimate: ($0.45)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 2 | ($0.24) | ($0.20) | ($0.22) |
| Q2 2017 | 2 | ($0.23) | ($0.21) | ($0.22) |
| Q3 2017 | 2 | ($0.21) | ($0.12) | ($0.17) |
| Q4 2017 | 2 | ($0.19) | ($0.10) | ($0.15) |
| Q1 2018 | 1 | ($0.17) | ($0.17) | ($0.17) |
| Q2 2018 | 1 | ($0.13) | ($0.13) | ($0.13) |
| Q3 2018 | 1 | ($0.09) | ($0.09) | ($0.09) |
| Q4 2018 | 1 | ($0.06) | ($0.06) | ($0.06) |
(Data provided by Zacks Investment Research)
Dividend History for Ironwood Pharmaceuticals (NASDAQ:IRWD)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Ironwood Pharmaceuticals (NASDAQ:IRWD)Insider Ownership Percentage: 7.63%
Institutional Ownership Percentage: 97.90%
Insider Trades by Quarter for Ironwood Pharmaceuticals (NASDAQ:IRWD)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 9/5/2017 | Julie Mchugh | Director | Sell | 1,500 | $16.16 | $24,240.00 | |
| 8/18/2017 | Gina Consylman | Insider | Sell | 207 | $14.34 | $2,968.38 | |
| 6/22/2017 | Halley E Gilbert | Insider | Sell | 35,000 | $19.75 | $691,250.00 | |
| 5/15/2017 | Thomas A Mccourt | Insider | Sell | 30,000 | $18.20 | $546,000.00 | |
| 2/14/2017 | Halley E Gilbert | Insider | Sell | 37,385 | $16.75 | $626,198.75 | |
| 1/12/2017 | Peter M Hecht | CEO | Sell | 65,987 | $15.67 | $1,034,016.29 | |
| 12/5/2016 | Lawrence S Olanoff | Director | Sell | 3,200 | $15.68 | $50,176.00 | |
| 9/6/2016 | Lawrence S Olanoff | Director | Sell | 3,200 | $13.72 | $43,904.00 | |
| 8/19/2016 | Gina Consylman | Insider | Sell | 207 | $13.54 | $2,802.78 | |
| 6/3/2016 | Lawrence S Olanoff | Director | Sell | 2,200 | $12.92 | $28,424.00 | |
| 5/25/2016 | Halley E Gilbert | Insider | Sell | 20,275 | $12.19 | $247,152.25 | |
| 3/11/2016 | Peter M Hecht | CEO | Sell | 120,000 | $10.72 | $1,286,400.00 | |
| 3/7/2016 | Lawrence S Olanoff | Director | Sell | 2,200 | $11.11 | $24,442.00 | |
| 2/24/2016 | Edward P Owens | Director | Buy | 10,000 | $8.32 | $83,200.00 | |
| 2/24/2016 | Gina Consylman | CAO | Sell | 420 | $8.50 | $3,570.00 | |
| 2/24/2016 | Mark G Currie | Insider | Sell | 152,154 | $8.53 | $1,297,873.62 | |
| 2/24/2016 | Thomas Graney | CFO | Sell | 563 | $8.50 | $4,785.50 | |
| 12/15/2015 | Peter M. Hecht | CEO | Sell | 73,418 | $11.07 | $812,737.26 | |
| 12/7/2015 | Lawrence S Olanoff | Director | Sell | 2,200 | $11.77 | $25,894.00 | |
| 9/4/2015 | Lawrence S Olanoff | Director | Sell | 3,725 | $10.97 | $40,863.25 | |
| 3/17/2015 | Peter M Hecht | CEO | Sell | 200,000 | $15.62 | $3,124,000.00 | |
| 3/12/2015 | Joseph C Cook Jr | Director | Sell | 5,883 | $15.54 | $91,421.82 | |
| 3/10/2015 | Bryan E Roberts | Director | Sell | 95,998 | $15.20 | $1,459,169.60 | |
| 3/3/2015 | Peter M Hecht | CEO | Sell | 63,442 | $15.75 | $999,211.50 | |
| 2/20/2015 | Joseph C Cook Jr | Director | Sell | 35,500 | $15.60 | $553,800.00 | |
| 12/15/2014 | Bryan E Roberts | Director | Sell | 19,792 | $15.20 | $300,838.40 | |
| 6/12/2014 | Bryan E Roberts | Director | Sell | 200,000 | $14.24 | $2,848,000.00 | |
| 5/29/2014 | Michael J Higgins | COO | Sell | 50,000 | $14.56 | $728,000.00 | |
| 5/22/2014 | Mark Currie | Insider | Sell | 25,000 | $13.93 | $348,250.00 | |
| 4/24/2014 | Mark Currie | Insider | Sell | 25,000 | $11.67 | $291,750.00 | |
| 1/23/2014 | Mark Currie | Insider | Sell | 20,000 | $14.38 | $287,600.00 | |
| 1/14/2014 | Bryan Roberts | Director | Sell | 21,200 | $12.57 | $266,484.00 | |
| 1/13/2014 | Bryan Roberts | Director | Sell | 823,350 | $12.71 | $10,464,778.50 | |
| 1/6/2014 | Bryan Roberts | Director | Sell | 55,450 | $12.01 | $665,954.50 | |
| 11/7/2013 | Terrance Mcguire | Director | Sell | 2,083 | $9.11 | $18,976.13 | |
| 6/17/2013 | Michael J Higgins | COO | Sell | 150,000 | $11.74 | $1,761,000.00 | |
| 3/11/2013 | Thomas A Mccourt | Insider | Sell | 40,000 | $17.00 | $680,000.00 | |
| 11/5/2012 | Peter M Hecht | CEO | Buy | 50,000 | $11.65 | $582,500.00 | |
| 10/8/2012 | Fmr Llc | Insider | Sell | 19,305 | $13.02 | $251,351.10 | |
(Data available from 1/1/2013 forward)
Headline Trends for Ironwood Pharmaceuticals (NASDAQ:IRWD)
Latest Headlines for Ironwood Pharmaceuticals (NASDAQ:IRWD)
| Source: |
|
| Date | Headline |
|---|
 | -$0.23 EPS Expected for Ironwood Pharmaceuticals, Inc. (IRWD) This Quarter
www.americanbankingnews.com - September 22 at 6:22 PM |
 | ETFs with exposure to Ironwood Pharmaceuticals, Inc. : September 13, 2017
finance.yahoo.com - September 14 at 6:33 AM |
| Ironwood Pharmaceuticals, Inc. (IRWD) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - September 12 at 6:56 AM |
 | TiGenix strengthens US operations with senior appointments
feeds.benzinga.com - September 12 at 1:34 AM |
| Ironwood Pharmaceuticals, Inc. :IRWD-US: Earnings Analysis: Q2, 2017 By the Numbers : September 11, 2017
finance.yahoo.com - September 11 at 8:42 PM |
| Ironwood Pharmaceuticals, Inc. (IRWD) Director Sells $24,240.00 in Stock
www.americanbankingnews.com - September 7 at 8:28 PM |
 | Form 8-K IRONWOOD PHARMACEUTICALS For: Sep 01
www.streetinsider.com - September 6 at 7:58 PM |
| Ironwood Pharmaceuticals Announces Leadership Change
finance.yahoo.com - September 6 at 7:58 PM |
| Contrasting Merrimack Pharmaceuticals (MACK) and Ironwood Pharmaceuticals (IRWD)
www.americanbankingnews.com - September 5 at 6:16 AM |
| $68.04 Million in Sales Expected for Ironwood Pharmaceuticals, Inc. (IRWD) This Quarter
www.americanbankingnews.com - September 5 at 3:00 AM |
| Why Is Ironwood (IRWD) Down 4.1% Since the Last Earnings Report?
finance.yahoo.com - September 4 at 6:52 PM |
| Ironwood Pharmaceuticals, Inc. (IRWD) Expected to Post Earnings of -$0.23 Per Share
www.americanbankingnews.com - September 4 at 12:20 AM |
| Ironwood Pharmaceuticals, Inc. (IRWD) Upgraded to Hold at ValuEngine
www.americanbankingnews.com - September 3 at 8:54 AM |
| Ironwood Pharmaceuticals to Present at Upcoming September Investor Conferences
finance.yahoo.com - August 31 at 8:00 PM |
| Ironwood Pharmaceuticals, Inc. (IRWD) Stock Rating Reaffirmed by Mizuho
www.americanbankingnews.com - August 26 at 8:32 PM |
| Ironwood Pharmaceuticals, Inc. (IRWD) Short Interest Up 16.0% in August
www.americanbankingnews.com - August 26 at 1:20 AM |
| Ironwood Pharmaceuticals, Inc. (IRWD) Raised to "Sell" at BidaskClub
www.americanbankingnews.com - August 25 at 7:50 PM |
 | Interesting IRWD Put And Call Options For October 20th
www.nasdaq.com - August 24 at 8:04 AM |
| Today's Research Reports on Stocks to Watch: Medtronic and Ironwood Pharmaceuticals
finance.yahoo.com - August 24 at 8:04 AM |
| Ironwood Pharma's Combination Gout Drug Gets FDA Approval
www.nasdaq.com - August 23 at 5:57 AM |
| Ironwood Pharma's Combination Gout Drug Gets FDA Approval
finance.yahoo.com - August 23 at 5:57 AM |
| FDA approves Ironwood Pharma's gout drug
finance.yahoo.com - August 21 at 7:09 PM |
| Ironwood Shares Jump on FDA Approval for Hyperuricemia Drug - Biotech Movers
finance.yahoo.com - August 21 at 7:09 PM |
| Ironwood Pharma Muted Despite FDA Approval
finance.yahoo.com - August 21 at 7:09 PM |
| Ironwood gets FDA approval for new drug for gout
finance.yahoo.com - August 21 at 7:09 PM |
| Cowen and Company Analysts Give Ironwood Pharmaceuticals, Inc. (IRWD) a $20.00 Price Target
www.americanbankingnews.com - August 21 at 6:02 PM |
 | Generic Drugs Stock Performance Review -- Patheon, Zoetis, Ironwood Pharma, and Medicines Co.
www.prnewswire.com - August 21 at 8:52 AM |
| Ironwood Pharma (IRWD) Announces FDA Approval of DUZALLO for Treatment of Hyperuricemia in Patients with Uncontrolled Gout
www.streetinsider.com - August 21 at 8:52 AM |
| Ironwood Pharmaceuticals Announces FDA Approval of DUZALLO® (lesinurad and allopurinol) for the Treatment of Hyperuricemia in Patients with Uncontrolled Gout
finance.yahoo.com - August 21 at 8:52 AM |
| Ironwood Pharmaceuticals, Inc. (IRWD) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - August 18 at 6:40 AM |
| See what the IHS Markit Score report has to say about Ironwood Pharmaceuticals Inc.
finance.yahoo.com - August 12 at 12:21 AM |
| FY2021 EPS Estimates for Ironwood Pharmaceuticals, Inc. Reduced by Analyst (IRWD)
www.americanbankingnews.com - August 7 at 10:22 AM |
| Ironwood Pharmaceuticals, Inc. (IRWD) Given a $20.00 Price Target by Cowen and Company Analysts
www.americanbankingnews.com - August 5 at 9:56 PM |
| Ironwood Pharmaceuticals, Inc. (IRWD) Posts Quarterly Earnings Results, Misses Expectations By $0.05 EPS
www.americanbankingnews.com - August 5 at 8:22 PM |
| Edited Transcript of IRWD earnings conference call or presentation 3-Aug-17 8:30pm GMT
finance.yahoo.com - August 4 at 8:13 PM |
| ETFs with exposure to Ironwood Pharmaceuticals, Inc. : August 4, 2017
finance.yahoo.com - August 4 at 1:08 AM |
| Ironwood Pharmaceuticals, Inc. – Value Analysis (NASDAQ:IRWD) : August 4, 2017
finance.yahoo.com - August 4 at 1:08 AM |
| Ironwood Pharmaceuticals Provides Second Quarter 2017 Investor Update
finance.yahoo.com - August 3 at 8:08 PM |
| Ironwood reports 2Q loss
finance.yahoo.com - August 3 at 8:08 PM |
| Mizuho Reiterates Buy Rating for Ironwood Pharmaceuticals, Inc. (IRWD)
www.americanbankingnews.com - August 2 at 8:22 PM |
| Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Cut to Sell at BidaskClub
www.americanbankingnews.com - July 31 at 4:29 PM |
| Zacks: Brokerages Anticipate Ironwood Pharmaceuticals, Inc. (IRWD) Will Announce Quarterly Sales of $68.48 Million
www.americanbankingnews.com - July 31 at 8:18 AM |
| Ironwood Pharmaceuticals, Inc. (IRWD) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - July 24 at 9:18 AM |
| Wells Fargo & Company Analysts Give Ironwood Pharmaceuticals, Inc. (IRWD) a $19.00 Price Target
www.americanbankingnews.com - July 23 at 10:41 PM |
| Ironwood Pharmaceuticals, Inc. (IRWD) Earns Outperform Rating from Cowen and Company
www.americanbankingnews.com - July 23 at 3:04 PM |
| Ironwood Pharmaceuticals, Inc. (IRWD) Given Buy Rating at Mizuho
www.americanbankingnews.com - July 23 at 3:04 PM |
| Ironwood Pharmaceuticals Reports Positive Top-line Results from IW-3718 Phase IIb Trial in Uncontrolled Gastroesophageal Reflux Disease
finance.yahoo.com - July 22 at 10:15 PM |
| J P Morgan Chase & Co Reiterates "Neutral" Rating for Ironwood Pharmaceuticals, Inc. (IRWD)
www.americanbankingnews.com - July 22 at 2:53 PM |
| Ironwood Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : IRWD-US : July 21, 2017
finance.yahoo.com - July 22 at 2:16 AM |
| Ironwood's Pipeline Needs Work, Analyst Downgrades
finance.yahoo.com - July 22 at 2:16 AM |
Ironwood Pharmaceuticals (IRWD) Chart for Saturday, September, 23, 2017
